New drug combo targets tough cancers in early trial
NCT ID NCT05789069
First seen Nov 21, 2025 · Last updated Jun 17, 2026 · Updated 26 times
Summary
This early-phase study tests a new drug, HFB200603, alone or with another drug (tislelizumab) in 83 adults with advanced solid tumors like kidney, lung, or skin cancer. The main goal is to find safe doses and check for side effects. Participants receive increasing doses to see how well the combination works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Centro Ricerche Cliniche di Verona s.r.l.
Verona, 37134, Italy
-
Clinica Universidad de Navarra - Madrid
Madrid, 28027, Spain
-
Clinica Universidad de Navarra - Pamplona
Pamplona, 31008, Spain
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States
-
Hospital Clinico Universitario de Valencia
Valencia, 46010, Spain
-
Istituto Nazionale Tumori IRCCS Fondazione G. Pascale
Naples, 80131, Italy
-
New Experimental Therapeutics of Virginia - NEXT Oncology
Fairfax, Virginia, 22031, United States
-
South Texas Accelerated Research Therapeutics (START) Madrid - CIOCC
Madrid, 28050, Spain
-
South Texas Accelerated Research Therapeutics (START) Madrid - Hospital Fundacion Jimenez Diaz
Madrid, 28040, Spain
-
UOC Fase I - Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore
Rome, 00168, Italy
-
USC Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.